Latest Breaking News On - Platinum resistant ovarian cancer - Page 1 : comparemela.com

Repare Therapeutics Announces Fast Track Designation Granted by the FDA for Lunresertib in Combination with Camonsertib for the Treatment of Platinum-Resistant Ovarian Cancer

Repare Therapeutics Announces Fast Track Designation Granted by the FDA for Lunresertib in Combination with Camonsertib for the Treatment of Platinum-Resistant Ovarian Cancer
wallstreet-online.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wallstreet-online.de Daily Mail and Mail on Sunday newspapers.

Maria koehlerDrug administrationCompany nasdaqRepare therapeutics incPlatinum resistant ovarian cancerFast trackExecutive vice presidentChief medical officerFast track designation

Shattuck Labs Reports First Quarter 2024 Financial Results and Recent Business Highlights

02.05.2024 - - Completed additional enrollment in Phase 1B dose-expansion cohorts for TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) patients in the first quarter of 2024; updated combination data expected at the European Society of Hematology (EHA) 2024 .

United statesNorth carolinaMirvetuximab soravtansineConor richardsonClay siegallKate sasserTaylor schreiberExchange commissionOno pharmaceutical co ltdDevelopment rd expensesShattuck labs incAmerican association for cancer researchCancer researchAnnual meetingChief executive officerOno pharma

Dr Konecny on the FDA Approval of Mirvetuximab Soravtansine for FRα+ Platinum-Resistant Ovarian Cancer

Gottfried E. Konecny, MD, discusses the FDA approval of mirvetuximab soravtansine for patients with FRα-positive, platinum-resistant ovarian cancer.

United statesLos angelesGottfriede konecnyUniversity of californiaDepartment of medicineBoxed warningFda approval of mirvetuximab soravtansinePatients with frα positivePlatinum resistant ovarian cancer

Natera to Present New Data at the 2024 SGO Annual Meeting on Women s Cancer, Following Recent Medicare Coverage Decisions in Ovarian and Breast Cancers -March 12, 2024 at 08:08 am EDT

Natera to Present New Data at the 2024 SGO Annual Meeting on Women s Cancer, Following Recent Medicare Coverage Decisions in Ovarian and Breast Cancers -March 12, 2024 at 08:08 am EDT
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United statesSan carlosFloortje backesAdam elnaggarMichael toboniSarah leeAnne kniselyNatera incSociety of gynecologic oncologyClinical laboratory improvement amendmentsGynecologic oncologyAnnual meetingDrive purposeOvarian cancerMolecular mirrorsMike shalamov

#VisualAbstract: Mirvetuximab soravtansine-gynx compared to chemotherapy in folate receptor alpha-positive platinum resistant ovarian cancer led to improved survival

1. Mirvetuximab soravtansine-gynx (MIRV) significantly improved progression-free survival, objective response, and overall survival compared to chemotherapy in patients with platinum-resistant, folate receptor alpha (FRα)-positive ovarian cancer 2. Ocular adverse events were more common with MIRV, which included blurry vision, keratopathy, and dry eyes. Evidence Rating: Level 1 (Excellent) Study rundown: Mirvetuximab soravtansine-gynx (MIRV), is an antibody–drug conjugate

Minute medicine incFolate receptor aMirv therapyMirvetuximab soravtansine gynxOvarian cancerPlatinum resistant ovarian cancer